A Phase Ib/II Study of AK138D1 as Monotherapy and in Combination With Ivonescimab in Patients With Advanced Non-Small Cell Lung Cancer
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 265
- 试验地点
- 2
研究概览
简要总结
The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of AK138D1 as monotherapy or in combination with ivonescimab in patients with advanced non-small cell lung cancer.
Participants will receive study treatment with AK138D1 alone or in combination with ivonescimab, undergo safety assessments and tumor evaluations, and be followed for treatment tolerability, antitumor activity, and clinical outcomes.
详细描述
This is a multicenter, open-label phase Ib/II study of AK138D1 as monotherapy or in combination with ivonescimab in patients with advanced non-small cell lung cancer. The phase Ib portion is designed to evaluate the safety, tolerability, and preliminary antitumor activity of AK138D1 in combination with ivonescimab. The phase II portion is designed to evaluate the safety and efficacy of AK138D1 as monotherapy or in combination with ivonescimab.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The subject must sign the written informed consent form (ICF) voluntarily;
- •At enrollment, aged ≥ 18 to ≤ 75 years, both males and females are eligible;
- •Has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
- •Has a life expectancy of ≥ 3 months;
- •Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.
- •Has Stage IIIB/IIIC or IV non-small cell lung cancer (NSCLC) (American Joint Committee on Cancer [AJCC]).
- •Adequate organ function.
排除标准
- •Concomitant participation in another clinical study, unless it is a non-interventional clinical study or the follow-up period of an interventional study;
- •Presence of active central nervous system (CNS) metastases.
- •Live vaccines or attenuated live vaccines administered within 4 weeks prior to the first dose, or planned to be administered during the study; use of inactivated vaccines is allowed;
- •Untreated subjects with active hepatitis B or active hepatitis C;
- •Known active pulmonary tuberculosis (TB); subjects with suspected active TB must undergo appropriate clinical assessment to rule out the presence of active disease;
- •Known active syphilis infection;
- •Subjects with known allergy to any component of any study drug; and with a history of known severe hypersensitivity reactions to other monoclonal antibodies;
- •Other reasons for ineligibility as evaluated by investigator.
研究组 & 干预措施
AK138D1 + Ivonescimab + Carboplatin
AK138D1, ivonescimab and carboplatin will be administered at pre-specified dose levels.
干预措施: AK138D1 (Drug)
AK138D1
AK138D1 will be administered at pre-specified dose levels.
干预措施: AK138D1 (Drug)
AK138D1+ Ivonescimab
AK138D1 and ivonescimab will be administered at pre-specified dose levels.
干预措施: AK138D1 (Drug)
AK138D1 + Ivonescimab + Carboplatin
AK138D1, ivonescimab and carboplatin will be administered at pre-specified dose levels.
干预措施: Ivonescimab (Drug)
AK138D1 + Ivonescimab + Carboplatin
AK138D1, ivonescimab and carboplatin will be administered at pre-specified dose levels.
干预措施: Carboplatin (Drug)
AK138D1+ Ivonescimab
AK138D1 and ivonescimab will be administered at pre-specified dose levels.
干预措施: Ivonescimab (Drug)
结局指标
主要结局
未指定
次要结局
- Progression Free Survival (PFS)(Up to approximately 2 years)